This week’s plant medicine newsletter covers THC-rich cannabis extracts and long-term cancer survival, CBD’s potential for skin conditions and chronic pain, microdosing cannabinoids for Alzheimer’s dementia, and a surprising new clinical trial on ketamine for severe depression.
Noteworthy Read
Cannabis Treatment Associated with Prolonged Survival in Patients with Aggressive Form of Cancer (NORML)
NORML reports on a case series showing that cannabis-based therapies (and particularly THC-rich extracts) were associated with unexpectedly prolonged survival in patients with an aggressive form of cancer.
Read more
View more in THC
More Noteworthy Reading
Therapeutic Potential of CBD in Skin Conditions (Journal of Cosmetic Dermatology)
A new review highlights CBD’s promising dermatological applications — including reducing inflammation, regulating sebum, supporting wound healing, and modulating skin barrier function — while noting that clinical trials in humans remain limited.
Read more
View more in CBD
THC/CBD Microdosing Shows Impact on Alzheimer’s Dementia (Hemp Gazette)
A study summarised by Hemp Gazette found that microdoses of THC and CBD may slow cognitive decline and reduce behavioral symptoms associated with Alzheimer’s, with the combination outperforming single-compound treatments in early models.
Read more
View more in Endocannabinoid System
CBD & Beta-Caryophyllene for Chronic Inflammatory Pain (Pharmacological Research)
A preclinical study found that CBD combined with beta-caryophyllene produced strong synergistic anti-inflammatory and analgesic effects in chronic pain models, outperforming either compound alone.
Read more
View more in CBD
Research Round-Up
Clinical Trial: Ketamine Fails to Outperform Placebo for Severe Depression (PsyPost)
A newly published clinical trial found that ketamine did not significantly outperform placebo in patients with severe depression, raising questions about expectancy effects and the real-world consistency of ketamine’s antidepressant benefits.
Read more
View more in Psychedelics
A heartfelt thank you to all of the CBD brands whose generous support makes it possible for Project CBD to bring you the latest research and journalism on plant medicine every week. We couldn’t do this work without you.
Be the first to comment